Thank you for your interest in SHOW 2019!

We continue to evolve and improve SHOW based on participant feedback and the breakneck pace of innovation in the arena of hepatic oncology. This year we have expanded the scope of SHOW to include hot topics including discussions on Microsatellite Instability, Immuno oncology, Right Sided Primary (RSP) in colorectal cancer, and a host of novel agents and therapies that have direct impact on your day to day clinical practise. As in the past, to keep the discussion flowing we will continue with topic-based panels and our signature ‘SHOW case based expert panels’, each designed to simulate thought and discussion.

As always, the main objective of SHOW is to present practical perspectives on the treatment of HPB related cancers in the setting of community-based practice. In this way, we are representing specialties involved in liver-directed cancer care to facilitate cross-specialty dialogue through case-based review, lectures and active audience participation. Our faculty consists of internationally recognized representatives from medical oncology, surgical oncology, hepatobiliary surgery, interventional radiology, radiology and radiation oncology who have embraced and incorporated multidisciplinary care into their daily practices. We will also provide a Canadian perspective on the topics.

As part of our ongoing commitment to developing a comprehensive and a truly multidisciplinary program, we are proud to receive the endorsement of the Canadian Association of Interventional Radiologists (CAIR) and BC Community Oncology Trialists (BCCOT).
In an effort to comply with new compliance regulations we have also changed the format of SHOW to a two full day meeting.
We sincerely hope that you consider joining us at SHOW 2019.

Registration is limited to 200 and early bird discounts are in effect until December 10, 2018

Yours truly,

SHOW Chairs
David Liu, MD (Vancouver, BC)
Wendy Lam, MD (Burnaby, BC)
Jason Wong, MD (Calgary, AB) Education & Ethics Officer

SHOW Planning Committee

Paul Hansen, MD (Portland, OR)
Andrew Kennedy, MD (Nashville, TN)
Peter Kim, MD (Vancouver, BC)

Learning Objectives:

    • Establish principles of liver-directed locoregional therapy in the setting of gastric cancer, pancreatic neuroendocrine disease, hepatocellular carcinoma and metastatic colorectal carcinoma.
    • Review evidence base for systemic, surgical, ablative and embolic strategies in liver-directed therapies in HCC mCRC pNET and gastic cancer.
    • Provide context for locoregional therapy as it relates to the timing of systemic therapies.
    • Engage in case-based panels that exemplify the role of multidisciplinary board review
    • Demonstrate the synergies and optimization of therapeutic options in the treatment of both primary and metastatic liver cancer
    • Create a forum for open discussion and cross disciplinary knowledge translation
    • Assess recent advances in systemic treatment of gastric cancer, hepatocellular carcinoma, pancreatic neuroendocrine disease, and colorectal cancer
    • Facilitate direct discussion and interaction with world recognized disease experts

Target Audience

    • Physicians, nurses, allied health professionals, and trainees with a scope of practice that involves management of both primary and hepatic neoplasia. Topics and themes will focus on practical and community-based practice.